Related Experiment Videos
COMT inhibitors in Parkinson's disease
J Rivest1, C L Barclay, O Suchowersky
1Centre Universitaire de Santé de l'Estrie, Fleurimont, Quebec, Canada.
Summary
New Parkinson's medications, COMT inhibitors like tolcapone and entacapone, improve levodopa's effectiveness. While beneficial for motor function and "on" time, tolcapone
Area of Science:
- Pharmacology
- Neurology
- Drug Development
Background:
- Parkinson's disease (PD) management often involves levodopa.
- Peripheral levodopa degradation by catechol-o-methyl-transferase (COMT) limits its efficacy.
- COMT inhibitors offer a novel therapeutic approach.
Purpose of the Study:
- To evaluate the pharmacokinetic and clinical effects of COMT inhibitors (tolcapone, entacapone).
- To assess their impact on levodopa bioavailability and PD symptom management.
- To identify potential side effects and safety concerns.
Main Methods:
- Pharmacokinetic studies analyzing levodopa's half-life and area under the curve.
- Clinical trials in stable and fluctuating PD patients.
- Review of reported adverse events, including liver enzyme elevations and hepatitis.
Main Results:
- COMT inhibitors significantly prolong levodopa's half-life and increase its bioavailability.
- Clinical benefits include improved motor function, reduced levodopa dosage, and increased "on" time in fluctuating PD.
- Common side effects include diarrhea; serious concerns involve elevated liver enzymes and rare cases of fulminant hepatitis with tolcapone.
Conclusions:
- COMT inhibitors enhance levodopa therapy for Parkinson's disease.
- Tolcapone's association with severe liver toxicity necessitates cautious use and monitoring.
- Close monitoring of liver function is crucial for all nitrocatechol COMT inhibitors due to potential class effects.